Amgen-backed immuno-oncology spinout Immatics has gone public through a reverse merger with special purpose acquisition company Arya Sciences.
Immatics, a Germany-based cancer immunotherapy developer backed by pharmaceutical company Amgen and telecommunications firm Swisscom, has executed a reverse merger with special purpose acquisition vehicle Arya Sciences Acquisition.
The company’s shares opened at $15.05 on the Nasdaq Capital Market late last week, closing at $14.40 yesterday to give Immatics a market cap of $5.64bn.
Proceeds from the transaction amounted to approximately $253m, consisting of $149m held in Arya’s trust account and a $104m private investment in public equity (PIPE) deal.
…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
